Lakefront Biotherapeutics (GLPGF) Current Deferred Revenue (2013 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Current Deferred Revenue for 14 consecutive years, with $37463.9 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 99.98% year-over-year to $37463.9 in Q1 2026; TTM through Mar 2026 was $37463.9, a 99.98% decrease from a year earlier, with the FY2025 full-year figure at $36154.0, down 99.99% from the prior year.
• Current Deferred Revenue was $37463.9 for Q1 2026 at Lakefront Biotherapeutics, up from $37249.4 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $373.0 billion in Q4 2022 and troughed at $37249.4 in Q4 2025.
• A 5-year average of $28.9 billion and a median of $260.6 million in 2025 frame the typical range for Current Deferred Revenue.
• The widest YoY moves for Current Deferred Revenue: up 6.08% in 2025, down 99.99% in 2025.
• Over 5 years, Current Deferred Revenue stood at $373.0 billion in 2022, then plunged by 99.93% to $275.7 million in 2023, then fell by 9.9% to $248.4 million in 2024, then slumped by 99.99% to $37249.4 in 2025, then rose by 0.58% to $37463.9 in 2026.
• The last three Current Deferred Revenue figures came in at $37463.9 (Q1 2026), $37249.4 (Q4 2025), and $269.0 million (Q3 2025), per Business Quant data.